3,4-Dibromo-2-hydroxy-N-phenylbenzamide | 140681-90-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3,4-Dibromo-2-hydroxy-N-phenylbenzamide
• CAS: 140681-90-9
• 化学式: C₁₃H₉Br₂NO₂
• 分子量: 371.02
• InChiKey: XFKLCOFARDPKCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Ointment bases and ointments
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0137212A2

  公开（公告）日：1985-04-17

  This invention provides an ointment base containing, as a solvent for the medicament, an imidazolidinone derivative represented by the formula wherein X' and X2 each represent a lower alkyl group, and an ointment comprising the medicament and the ointment base.

  本发明提供了一种软膏基质，其中含有一种咪唑烷酮衍生物（作为药物的溶剂），该衍生物由式（其中 X' 和 X2 各代表一个低级烷基）表示，还提供了一种软膏，其中包括药物和软膏基质。
• Compositions and Methods for Treating Vaginal Infections and Pathogenic Vaginal Biofilms
  申请人：Toltec Pharmaceuticals, Llc

  公开号：EP2529723A2

  公开（公告）日：2012-12-05

  The present invention generally relates to methods and compositions for treating pathogenic vaginal biofilms. More specifically, the invention relates to pharmaceutical compositions comprising a combination of boric acid and diethylaminetetracetic acid (EDTA) and to methods of using such compositions to treat or prevent biofilm formation associated with vaginal infections, such as bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), trichomoniasis or mixed infections.

  本发明一般涉及治疗致病性阴道生物膜的方法和组合物。更具体地说，本发明涉及由硼酸和二乙胺四乙酸（EDTA）组合而成的药物组合物，以及使用这种组合物治疗或预防与阴道感染（如细菌性阴道病（BV）、外阴阴道念珠菌病（VVC）、滴虫病或混合感染）相关的生物膜形成的方法。
• REVERSELY THERMO-REVERSIBLE HYDROGEL COMPOSITIONS
  申请人：Broda Technologies Co., Ltd

  公开号：EP2689774A1

  公开（公告）日：2014-01-29

  A reversely thermo-reversible hydrogel composition comprising a water soluble block copolymer comprising at least two blocks of polyethylene oxide and at least one block of polypropylene oxide, and at least one associative gelling adjuvant having water solubility less than 0.5 g/100ml, preferably less than 0.3 g/100 ml at 20 °C, and being capable of forming water soluble inter-molecular complexes with the water soluble block copolymer in water. The hydrogel composition exhibits improved gelling efficiency, enhanced solubility and/or stability for water sparely soluble and insoluble pharmaceutical agents. The hydrogel compositions are useful in a variety of pharmaceutical and cosmetic products and applications, such as esophageal, otic, vaginal, rectal, ophthalmic, and treatments of disorders and imperfections of the skin.

  一种反向热可逆水凝胶组合物，它包含一种水溶性嵌段共聚物，该嵌段共聚物由至少两个聚环氧乙烷嵌段和至少一个聚环氧丙烷嵌段组成；以及至少一种缔合胶凝佐剂，该佐剂在 20 °C 时的水溶性小于 0.5 克/100 毫升，最好小于 0.3 克/100 毫升，并能与水溶性嵌段共聚物在水中形成水溶性分子间络合物。这种水凝胶组合物的胶凝效率提高，对水溶性和不溶性药剂的溶解度和/或稳定性增强。这种水凝胶组合物适用于各种医药和化妆品及应用，如食道、耳道、阴道、直肠、眼科以及皮肤疾病和瑕疵的治疗。
• Terconazole composition and method
  申请人：Curatek Pharmaceuticals Holding, Inc.

  公开号：US10398692B2

  公开（公告）日：2019-09-03

  An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of citric acid. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole.

  一种水性特康唑组合物包含至少约 0.4%（按重量计）溶于水的特康唑，以及特康唑结晶抑制量的柠檬酸。还描述了制备组合物的方法。这些组合物改善了特康唑的治疗释放。
• Composition and method for treatment of bacterial vaginal infections
  申请人：——

  公开号：US20040131686A1

  公开（公告）日：2004-07-08

  A gelled pharmaceutical composition suitable for the treatment of a bacterial vaginal infection comprises, on a total composition weight basis, about 0.1 to about 2 weight percent of benzydamine hydrochloride, about 0.5 to about 4 weight percent of a carbomer polymer, and about 3 to about 50 weight percent of propylene glycol, in water having a pH in the range of about 3.5 to about 6. Optionally, the gelled compositions can also contain polyethylene glycols, physiologically tolerable preservatives and electrolytes, as well as other pharmaceutically acceptable excipients.

  一种适用于治疗细菌性阴道感染的胶凝药物组合物，以组合物总重量为基准，包括约 0.1 至约 2 重量百分数的盐酸苄达明、约 0.5 至约 4 重量百分数的卡波姆聚合物和约 3 至约 50 重量百分数的丙二醇，在 pH 值范围为约 3.5 至约 6 的水中。可选地，胶化组合物还可以含有聚乙二醇、生理上可耐受的防腐剂和电解质，以及其他药学上可接受的赋形剂。